Manufacturer of Controlled Substances Notice of Registration, 77067 [E6-21872]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 246 / Friday, December 22, 2006 / Notices
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21873 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Registration
By Notice dated August 15, 2006, and
published in the Federal Register on
August 22, 2006, (71 FR 48947—48948),
Research Triangle Institute, Kenneth H.
Davis, Jr., Hermann Building, P.O. Box
12194, East Institute Drive, Research
Triangle, North Carolina 27709, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
Marihuana (7360) .........................
Cocaine (9041) .............................
I
II
jlentini on PROD1PC65 with NOTICES
The Institute will manufacture small
quantities of cocaine and marihuana
derivatives for use by their customers in
analytical kits, reagents, and reference
standards as directed by NIDA.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Research Triangle Institute to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Research Triangle Institute
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21872 Filed 12–21–06; 8:45 am]
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
National Institute of Corrections
Manufacturer of Controlled
Substances Notice of Registration
Solicitation for a Cooperative
Agreement—Transition From Jail to
the Community (TJC)
By Notice dated August 7, 2006, and
published in the Federal Register on
August 15, 2006, (71 FR 46922), Rhodes
Technologies, 498 Washington Street,
Coventry, Rhode Island 02816, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
AGENCY:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Thebaine (9333) ...........................
Noroxymorphone (9668) ..............
Fentanyl (9801) ............................
19:31 Dec 21, 2006
Jkt 211001
I
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for conversion and sale to dosage form
manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Rhodes Technologies to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Rhodes Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–21877 Filed 12–21–06; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Aug<31>2005
77067
PO 00000
Frm 00108
Fmt 4703
Sfmt 4703
National Institute of
Corrections, Department of Justice.
ACTION: Solicitation for a Cooperative
Agreement.
SUMMARY: The Department of Justice
(DOJ), National Institute of Corrections
(NIC) announces the availability of
funds in FY 2007 for a cooperative
agreement to initiate the project
‘‘Transition From Jail to the
Community’’ (TJC). A cooperative
agreement is a form of assistance
relationship where NIC is substantially
involved during the performance of the
award. An award will be made to an
organization who will, in concert with
NIC, identify the method and approach
in developing a jail/community
transition program.
An 18-month cooperative agreement
award will be made to an organization
that will help NIC design a jail/
community transition model that will
enhance the likelihood that persons
released from jails do not commit
crimes following release. Ultimately, the
transition model will be implemented in
a limited number of localities, the
impact will be evaluated and knowledge
will be shared broadly about what has
been learned through focused assistance
to those jurisdictions. During the initial
award, the model will be developed,
and two jurisdictions will be selected to
begin testing it before expanding
assistance (phase II) to include
approximately four additional
jurisdictions. Depending on the
successful applicant’s work plan, it is
anticipated that phase II work will begin
as a late task during this initial award
or as an early task in what, future
funding permitting, will be a subsequent
implementation award to the same or
different cooperative agreement
awardee. No local jurisdictions have
been identified as participants. NIC will
make participant selections with the
awardee at an appropriate point in the
approved work plan. NIC views this
effort as a comprehensive system change
effort that could reasonably take
jurisdictions at least two years to
implement.
DATES: The application must be received
by 4 p.m. on Thursday, February 1,
2007.
ADDRESSES: Mailed applications must be
sent to: Director, National Institute of
Corrections, 320 First Street, NW., Room
E:\FR\FM\22DEN1.SGM
22DEN1
]]>Agencies
[Federal Register Volume 71, Number 246 (Friday, December 22, 2006)]
[Notices]
[Page 77067]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21872]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances Notice of Registration
By Notice dated August 15, 2006, and published in the Federal
Register on August 22, 2006, (71 FR 48947--48948), Research Triangle
Institute, Kenneth H. Davis, Jr., Hermann Building, P.O. Box 12194,
East Institute Drive, Research Triangle, North Carolina 27709, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Cocaine (9041)............................. II
------------------------------------------------------------------------
The Institute will manufacture small quantities of cocaine and
marihuana derivatives for use by their customers in analytical kits,
reagents, and reference standards as directed by NIDA.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Research Triangle Institute to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Research Triangle Institute to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-21872 Filed 12-21-06; 8:45 am]
BILLING CODE 4410-09-P
